Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions-Reference-Cited by-同舟云学术

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

Published:2019-03-07 Issue:8 Volume:58 Page:578-588
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosomes Cancer

Author:

Stenzinger Albrecht¹^ORCID,Allen Jeffrey D.²,Maas Jörg³,Stewart Mark D.²,Merino Diana M.²,Wempe Madison M.²,Dietel Manfred⁴

Affiliation:

1. Institute of Pathology, University Hospital Heidelberg (on behalf of QuIP® GmbH, Berlin, Germany) Heidelberg Germany

2. Science Policy, Friends of Cancer Research Washington District of Columbia

3. Management DepartmentQuIP® GmbH Berlin Germany

4. Institute of Pathology, Charité Berlin (on behalf of QuIP® GmbH, Berlin, Germany) Berlin Germany

Funder

F. Hoffmann-La Roche AG

Merck Sharp and Dohme

Memorial Sloan-Kettering Cancer Center

Johns Hopkins University

Columbia University

Thermo Fisher Scientific

Regeneron Pharmaceuticals, Inc.

Pfizer

Merck

Illumina

Genentech

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/gcc.22733

Reference78 articles.

1. Neoantigens in cancer immunotherapy

2. Signatures of mutational processes in human cancer

3. Mutational heterogeneity in cancer and the search for new cancer-associated genes

4. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

5. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Cytopathology;Surgical Pathology Clinics;2024-09

2. The Open Pediatric Cancer Project;2024-07-11

3. Permutation-invariant linear classifiers;Machine Learning;2024-07-09

4. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee;Journal for ImmunoTherapy of Cancer;2024-07

5. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES);American Journal of Clinical Pathology;2024-05-12